**1. Introduction**

According to GLOBOCAN 2020, female breast cancer surpassed lung cancer as the leading cause of cancer globally in 2020, with 2.3 million new cases worldwide [1]. Breast cancer is a heterogeneous disease encompassing different entities with distinct morphological features and clinical behaviors. The St. Gallen guidelines, the American Society of Clinical Oncology, and the College of American Pathology have defined triple-negative breast cancer (TNBC) as breast cancer with:

1.Less than 1% of tumor cells expressing ER and PR via IHC [2].

2.Her-2-neu negative: Immunohistochemistry (IHC) staining of 0 or 1 +, a Fluorescent in-situ hybridization (FISH) result of less than 4.0 HER2 gene copies per nucleus, or FISH ratio of less than 1.8 (FISH to be done in case IHC is 2+, equivocal) [3].
